October is right around the corner, and to many, it is anticipated as Pink October for its significance with breast cancer awareness. Although breast cancer awareness is important, what is even more important is breast screening!
In the spirit of breast cancer awareness, MMD Group is proud to announce its recent partnership in the MENA region with Predilife, a French company specialized in personalized predictive medicine and solutions for breast cancer. Among these solutions are MammoRisk® and DenSeeMammo®, which were developed in collaboration with leading academic centers in Paris: Gustave Roussy and Institut Curie.
Why is predictive medicine important?
Breast cancer is the most common cancer among women with an increasing incidence worldwide. Yet, 90% of cancer cases can be cured if treated in the early stages.
Breast screenings are integral to women’s health. They provide the critical information that healthcare providers rely on for breast cancer detection. Breast density data rendered from mammograms, complimented with a polygenic score, and patient-specific data can help improve patient outcomes by paving the way for early detection. The good news is that MammoRisk® revolutionizes breast cancer screening by synergizing all the above-mentioned inputs to formulate a strategic 5-year protection plan based on a detailed report that showcases the patient risk and facilitated early detection.
MammoRisk®is a market leader providing a personalized screening solution for women above the age of 40, through a score that predicts the risk of developing cancer after 5 years, and suggests the appropriate personalized screening based on the risk.
How does it work?
The MammoRisk® software is based on machine learning, artificial intelligence (AI) algorithms which consider the below main risk factors for cancer prediction evaluation:
* Polygenic risk score is a genetic test that is currently unavailable in many parts of the world, however, Predilife exclusively can offer it through centers in France. The test is done by collecting saliva samples (via special kit) and sending them to France via DHL (all logistics are handled through MMD-Predilife). Then a report will be received from the lab in France.
The benefits of the women completing the exam are that the software will generate a report that includes an estimation of the breast cancer risk in 5 years:
Personalized follow-up plan (the concept of MammoRisk® test is not to know the risk only, however, to have the proper diagnosis follow-up plan to have higher chances of early detection)
Also, Predilife offers another complimentary solution, the DenSeeMammo®, which is FDA approved and CE marked. DenSeeMammo® is an AI-based solution that classifies the density of the breast mammogram in categories (A, B, C, D), from low to high risk according to the BI-RADS V.
Mammograms During Pink October
Mammograms account for the largest number of routine breast screenings. Most countries in the world have set organized screen programs during the month of October for women above a certain age to do a mammogram image. When getting a mammogram, the woman stands in front of the machine. The technologist places the breast onto a clear plastic plate, then lowers a second plate to gently compress tissue for imaging. The mammogram allows the radiologist to determine the breast tissue density and look for any suspicious changes to the breast tissues.
What about our #RISK-TAKER campaign?
We are currently striving for a surge in mammography screening in the MENA region, that is to ensure that women are keeping up with their bodies and maintain their well-being, as well as to encourage women to gain deeper insight into their risk of developing breast cancer by following up with MammoRisk®.
We want all women who are eligible to take the MammoRisk® test, hence become risk-takers. By doing so, test-takers will no longer look at the mammogram as an end result, but as a piece of partial information that will be entered to the AI-based too along with the polygenic test score, and the personal information. These factors together will allow MammoRisk® to calculate their personal risk of breast cancer in addition to develop a 5-year personalized screening plan. Take the risk assessment, get a 5-years personalized follow-up plan, contact us for more details about MammoRisk®!
|cookielawinfo-checbox-analytics||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".|
|cookielawinfo-checbox-functional||11 months||The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".|
|cookielawinfo-checbox-others||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.|
|cookielawinfo-checkbox-necessary||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".|
|cookielawinfo-checkbox-performance||11 months||This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".|